Hengrui Medicine: The drug application for marketing approval of Fumasuan Likang Kepuan Capsules has been accepted.

Hengrui Pharmaceuticals announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., has received a acceptance notification from the National Medical Products Administration for the application for market approval of Fulmaricran Lichang Ke Pian capsules. Another subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for SHR-1819 injection and SHR-1905 injection, and will begin the trials soon.